2023
DOI: 10.1016/j.cell.2022.12.038
|View full text |Cite
|
Sign up to set email alerts
|

Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
24
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8
2

Relationship

5
5

Authors

Journals

citations
Cited by 50 publications
(29 citation statements)
references
References 214 publications
1
24
0
Order By: Relevance
“…From the therapeutic perspective, additional simple and sensitive biomarkers should be identified to evaluate disease activity and forecast the disease course of patients with anti-MDA5+ DM. The selection of IFI44, Mx1, and IRF1 as targeted genes in this study was based on several considerations, including their previous identification as highly upregulated and specific interferonstimulated genes (21)(22)(23), the need to differentiate between IFN-I and IFN-II signaling pathways, and the importance of selecting genes with close expression and designing non-mutually exclusive primers for accurate and reliable detection using multiplex RT-qPCR assays. The application of multiplex RT-qPCR in this study of IFN-I scores in patients with anti-MDA5+ DM was innovative.…”
Section: Discussionmentioning
confidence: 99%
“…From the therapeutic perspective, additional simple and sensitive biomarkers should be identified to evaluate disease activity and forecast the disease course of patients with anti-MDA5+ DM. The selection of IFI44, Mx1, and IRF1 as targeted genes in this study was based on several considerations, including their previous identification as highly upregulated and specific interferonstimulated genes (21)(22)(23), the need to differentiate between IFN-I and IFN-II signaling pathways, and the importance of selecting genes with close expression and designing non-mutually exclusive primers for accurate and reliable detection using multiplex RT-qPCR assays. The application of multiplex RT-qPCR in this study of IFN-I scores in patients with anti-MDA5+ DM was innovative.…”
Section: Discussionmentioning
confidence: 99%
“…Raw FASTQ files were aligned to the GRCh38 reference genome and count matrices for cell barcodes and UMIs were generated for each sample by CellRanger (v3.0.1). Using the Seurat (v4.3.0) R package, samples were filtered from cells expressing any two lineage markers ( CD79A , CD3G , CD14 , and LILRA4 ) as these were considered doublets 70,71 . In the HC-INS dataset, doublet and nonviable cells were removed by excluding cells expressing <200 or <3000 genes, >10% mitochondrial genes, and <10% ribosomal protein genes.…”
Section: Methodsmentioning
confidence: 99%
“…In conclusion, while mice lacking IFN-γ were shown to be susceptible to infection by both viruses and bacterial pathogens capable of surviving macrophage-mediated phagocytosis [ 180 , 181 ], the study of MSMD patients has shown that human IFN-γ is primarily a macrophage-activating factor and appears less important for anti-viral immunity. Notably, while both type I and II IFNs induce the transcription factor IRF1, in vitro studies of cells obtained from unrelated children with inherited complete IRF1 deficiency and multiple, life-threatening diseases in early life caused by weakly virulent mycobacteria and related intra-macrophagic pathogens but no history of severe viral disease demonstrated that IRF1 is essential for IFN-γ-dependent macrophage immunity to mycobacteria, but largely redundant for type I IFN-dependent anti-viral immunity [ 182 ]. A recent study of a patient with inherited PD-1 deficiency and TB, who died of pulmonary autoimmunity, has also highlighted the indispensable role of human PD1 in governing both anti-mycobacterial immunity and self-tolerance and provided important mechanistic insights relevant for the treatment of cancer patients who receive immunotherapy with PD-1-directed checkpoint inhibitors, thereby exhibiting a high vulnerability to tuberculosis for previously unknown reasons.…”
Section: Defects In the Interferon Pathwaysmentioning
confidence: 99%